2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

 

ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers"

37 views
June 12, 2024

Chapters

Roginolisib's Role & Study Rationale

00:00

Phase I Trial Design & Demographics

03:02

Clinical Outcomes & Future Directions

05:31

Comments 0
Login to view comments. Click here to Login